Etanidazole

Drug Profile

Etanidazole

Alternative Names: DUP 453; NSC 301467; NSC 314055; Radinyl; SP 2508; SR 2508

Latest Information Update: 12 Jul 2002

Price : $50

At a glance

  • Originator National Cancer Institute (USA); Nonindustrial source; SRI International
  • Developer Bristol-Myers Squibb; Nonindustrial source; SRI International
  • Class Antineoplastics; Chemosensitisers; Nitroimidazoles; Radiosensitisers; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 18 Jan 2000 Roberts Pharmaceutical has been merged into Shire Pharmaceuticals Group
  • 10 Sep 1998 A study in patients with head and neck cancer has been added to the therapeutic trials section
  • 17 Nov 1994 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top